Lantheus Holdings, Inc. (LNTH) vs Neurocrine Biosciences, Inc. (NBIX)
- Lantheus Holdings, Inc. LNTH 99.70 −0.29%
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
Lantheus Holdings, Inc. and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $13.9B against $6.5B — 2.1× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.2× against 23.7×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 2.35%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 17.7%) and the higher return on invested capital (15.0% vs 14.7%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 18 and Lantheus Holdings, Inc. on 4.
Valuation
Profitability
| Metric | LNTH | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 60.14% | 97.94% | 53.94% |
| Operating margin | 19.43% | 23.56% | 0.00% |
| Net margin | 17.69% | 20.91% | 0.00% |
| Free cash flow margin | 25.24% | 25.80% | 0.00% |
| Return on equity | 22.21% | 22.09% | (0.40%) |
| Return on assets | 12.15% | 15.26% | (3.32%) |
| Return on invested capital | 14.65% | 15.04% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack